Patents Examined by J D Schultz
  • Patent number: 7846910
    Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment for ?-amyloid (A?) accumulation in brain comprising GCP-II (Glutamate carboxypeptidase-II) as an active ingredient, a composition for screening method of the same. GCP-II of the present invention not only degrades A? monomer and oligomer but also degrades soluble A? and insoluble A?, particularly aggregated A?, so that it can prevent the accumulation of A? in brain or reduce the accumulation, making it an excellent candidate for the therapeutic agent for Alzheimer's disease and Down's syndrome.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: December 7, 2010
    Assignee: Korea Center for Disease Control and Prevention
    Inventors: Sang-Mee Ahn, So Young Seo, San Sook Chae
  • Patent number: 7824912
    Abstract: The present invention is directed to methods for readily propagating somatic liver stem cells. The methods comprise enhancing guanine nucleotide (GNP) biosynthesis, thereby expanding guanine nucleotide pools. This in turn conditionally suppresses asymmetric cell kinetics in the explanted cells. The methods of the invention include pharmacological methods and genetic methods. For example, the resulting cultured somatic liver stem cells can be used for a variety of applications including cell replacement therapies, gene therapies, drug discovery applications, and tissue engineering applications, such as the generation of artificial liver.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: November 2, 2010
    Assignee: Massachusetts Institute of Technology
    Inventors: James L. Sherley, Krisha Panchalingam
  • Patent number: 7816104
    Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. The invention provides means and methods reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: October 19, 2010
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
  • Patent number: 7767803
    Abstract: The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2?-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: August 3, 2010
    Assignee: Archemix Corp.
    Inventors: John L. Diener, Paul Hatala, Jess Wagner-Whyte, Charles Wilson
  • Patent number: 7723316
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: May 25, 2010
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7674896
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: March 9, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • Patent number: 7629121
    Abstract: Human individuals at increased risk for vascular pathology are identified by determining whether the individuals' genome comprises a Notch1 allele predetermined to be associated with an increased risk for vascular pathology. Notch1 alleles are identified as being associated with increased risk for vascular pathology by detecting the presence of a same Notch allele in a plurality of persons with increased risk for vascular pathology.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: December 8, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Deepak Srivastava, Vidu Garg
  • Patent number: 7625702
    Abstract: A structure and method for forming single-stranded DNA segments/single-wall carbon nanotube complexes and a method of preparing single-stranded DNA segments. The method for forming single-stranded DNA segments/single-wall carbon nanotube complexes including: attaching single-stranded DNA segments to single-wall carbon nanotubes to form single-stranded DNA segment/single-wall carbon nanotube complexes, each of the single-stranded DNA segments having a same length of greater than 2,000 bases.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: December 1, 2009
    Assignee: International Business Machines Corporation
    Inventor: Jennifer Nam Cha
  • Patent number: 7618778
    Abstract: The described method provides, methods, and kits to produce, identify, catalog and classify a comprehensive collection of nucleic acid targets produced from a nucleic acid sample. The method, referred to as Cataloging and Classification of Sequence Tags, involves generating a set of target nucleic acid fragments; coupling the target nucleic acid fragments to a nucleic acid bridge comprising, for example, two or more primer binding sites and two recognition sites for cleavage at a site offset from the recognition site to the fragment's end; and cleaving the fragments to generate chimeric nucleic acids of known length. The nucleic acid bridge is thus disposed between the two nucleic acid fragments in the chimeric nucleic acid. The resulting duplex nucleic acids comprise a set of sequence tags (i.e., by amplification using universal primers), comprising an addressable portion, a target nucleic portion and a portion of the nucleic acid bridge.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: November 17, 2009
    Inventor: Joseph C. Kaufman
  • Patent number: 7615341
    Abstract: An gene was identified as a RA disease susceptibility gene on Human Chromosome 8, the gene coding a protein that has an amino acid sequence shown in SEQ. ID NO. 1 and that has such mutation that glycine is inserted as a 269th amino acid in the sequence. Moreover, it was found that mutation of the gene and the protein relate to onset of RA. Achieved is a method of evaluating with high accuracy the onset or onset possibility of RA by using the mutation.
    Type: Grant
    Filed: January 8, 2003
    Date of Patent: November 10, 2009
    Inventors: Shunichi Shiozawa, Koichiro Komai, Mikiko Nakatsukasa
  • Patent number: 7544638
    Abstract: This invention provides method and apparatus for performing chemical and biochemical reactions in solution using in situ generated photo-products as reagent or co-reagent. In particular, the present invention provides methods and devices for generating a photogenerated reaction in solution on a substrate comprising generating a light beam using an optical device system comprising a light source and a computer-controlled spatial optical modulator comprising a digital micromirror device and using the spatial optical modulator to direct light to fluidly isolated reaction sites under conditions such that a photogenerated reaction takes place. The method and apparatus of the present invention have applications in parallel synthesis of molecular sequence arrays on solid surfaces.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: June 9, 2009
    Assignees: The Regents of the University of Michigan, University of Houston
    Inventors: Xiaolian Gao, Xiaochuan Zhou, Erdogan Gulari
  • Patent number: 7511136
    Abstract: Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: March 31, 2009
    Assignee: Pfizer Italia S.r.l.
    Inventors: Raffaella Amici, Matteo D'Anello, Katia Martina, Barbara Salom, Anna Vulpetti
  • Patent number: 7498292
    Abstract: The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to methods for identifying autoinducer agonists and antagonists, as well as methods for regulating the activity of an autoinducer receptor, regulating biofilm formation, regulating growth or virulence of an organism in a subject, inhibiting the quorum sensing mechanism of an organism, and treating an infection in a subject caused by an organism possessing a quorum sensing mechanism which use the autoinducer analogs of the present invention.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: March 3, 2009
    Assignee: The Research Foundation of State University of New York
    Inventors: Hiroaki Suga, Yigong Bu
  • Patent number: 7491680
    Abstract: This invention provides method and apparatus for performing chemical and biochemical reactions in solution using in situ generated photo-products as reagent or co-reagent. In some embodiments, the present invention provides methods and devices for generating one or more selected multimers at specific reaction sites on a substrate comprising contacting the substrate with a liquid solution comprising photo-reagent precursors, isolating the reaction sites, selectively irradiating the reaction sites with a digital micromirror device, and contacting the substrate with monomers. The method and apparatus of the present invention have applications in parallel synthesis of molecular sequence arrays on solid surfaces.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: February 17, 2009
    Assignees: The Regents of the University of Michigan, University of Houston
    Inventors: Xiaolian Gao, Xiaochuan Zhou, Erdogan Gulari
  • Patent number: 7473671
    Abstract: A glycopeptide of the formula A1-A2-A3-A4-A5-A6-A7, in which each dash represents a covalent bond; wherein A1 comprises a modified or unmodified ?-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, guanidinyl, carbamoyl, or xanthyl; wherein each of A2 to A7 comprises a modified or unmodified ?-amino acid residue, whereby (i) A1 is linked to an amino group on A2, (ii) each of A2, A4 and A6 bears an aromatic side chain, which aromatic side chains are cross-linked together by two or more covalent bonds, and (iii) A7 bears a terminal carboxyl, ester, amide, or N-substituted amide group; and wherein one or more of A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, at least one of the sugar residues bearing one or more substituents of the formula YXR, N+(R1)=CR2R3, N=PR1R2R3, N+R1R2R3 or P+R1R2R3 in which Y is a singl
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 6, 2009
    Assignee: The Trustees of Princeton University
    Inventors: Daniel Kahne, Robert Kerns, Seketsu Fukuzawa, Min Ge, Christopher Thompson
  • Patent number: 7452858
    Abstract: Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: November 18, 2008
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Richard A. Hiles, Kathryn S. Prickett
  • Patent number: 7431685
    Abstract: The aim of the invention is to investigate the bonding of substances to target molecules. This is achieved by means of a densely packed device wherein various target molecules are bonded in a large number of sample areas. Cross-contamination and evaporation need to be minimized. The active surface of the sample areas have to be maximized. The inventive solution resides in the use of carrier plates, containing densely packed capillary structures and having a very large inner surface despite small outer dimensions. 1000 times more molecules can be bonded than on a flat outer surface of a comparable size. Cross contamination is avoided by the lack of cross links between the capillaries. Evaporation is minimized by a small outer surface. After the inner surface of the capillaries has been silanized, peptides and peptidomimetics are synthesized in a locally targeted manner.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: October 7, 2008
    Assignee: Laser- und Medizin Technologie GmbH
    Inventors: Andreas Frey, Juergen Helfman, Marcus Alexander Schmidt, Gerhard Mueller
  • Patent number: 7098192
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: August 29, 2006
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: James G. Karras
  • Patent number: 7091333
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: August 15, 2006
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
  • Patent number: 7087743
    Abstract: The present invention relates to novel oligonucleotide sequences and also to derivatives thereof. These novel oligonucleotide sequences are capable of hybridizing specifically with the gene or with a product of the gene encoding tyrosinase, or with the gene or a product of the gene encoding tyrosinase-related-protein 1 (TRP-1). The present invention also relates to the use of these novel oligonucleotide sequences as a depigmenting or bleaching agent in a cosmetic composition or in a dermatological composition.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: August 8, 2006
    Assignee: LVMH Recherche
    Inventors: Robin Kurfurst, Régine Joly